This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertake no obligation to update such statements.
Polyketides are structurally a very diverse family of natural products with diverse biological activities and pharmacological properties.  They are broadly divided into three classes: type I polyketides (often macrolides produced by multimodular megasynthases ), type II polyketides (often aromatic molecules produced by the iterative action of dissociated enzymes ), and type III polyketides (often small aromatic molecules produced by fungal species). Polyketide antibiotics , antifungals , cytostatics , anticholesteremic , antiparasitics , coccidiostats , animal growth promoters and natural insecticides are in commercial use. [ citation needed ]
The MEP pathway starts with the condensation of pyruvate and D-glyceraldehyde-3-phosphate to 1-deoxy-D-xylulose-5-phosphate (DXP or DOXP). The key isomers DMAPP and IPP are subsequently formed via a series of enzymatic steps starting with the conversion of DXP to 2C-methyl-D-erythritol-4-phosphate (MEP). Enzymes of this MEP pathway are attractive targets for the development of drugs targeting infectious diseases such as malaria and tuberculosis, because this pathway occurs in pathogenic prokaryotes but is absent in human metabolic pathways.